Five Prime reports Phase I data for cabiralizumab in pancreatic cancer
Five Prime Therapeutics Inc. (NASDAQ:FPRX) reported preliminary data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors and announced upcoming trials sponsored by partner Bristol-Myers Squibb Co. (NYSE:BMY).
Among 31 evaluable pancreatic cancer patients in the trial, cabiralizumab plus Opdivo led to an objective response rate (ORR) of 13%, including 4 partial responses in heavily pretreated patients without microsatellite instability (MSI), and a durable clinical benefit rate (CBR) of 16%. Five Prime said that historically, pancreatic cancer without MSI does not respond to monotherapy with drugs that inhibit PD-1...
BCIQ Target Profiles
Colony-stimulating factor 1 receptor (CSF1R) (C-FMS) (CD115)